Clinical trial NCT01776424: Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
Official title: A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Prevention & Control
Keywords: Cardiovascular events
Rivaroxaban
Xarelto
Anticoagulant
Blood thinner
Aspirin
ASA
Coronary artery disease
CAD
Peripheral artery disease
PAD
Artery disease
Coronary artery bypass graft
Stroke
Heart attack
Angina
Arterial vascular disease
Myocardial infarction
MI
Cardiovascular Death
CV Death
Heart disease
Lead sponsor: Bayer
Sponsor class: INDUSTRY
Collaborators: name: Population Health Research Institute
name: Janssen Research & Development, LLC
First posted: 2013-01-28
Enrollment: 27395
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The primary objectives of this study are:

* To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral artery disease (PAD);
* To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD.


Eligibility criteria: Inclusion Criteria:

- Meet criteria for CAD and/or PAD

Subjects with CAD must also meet at least one of the following criteria:

* Age ≥65, or
* Age \<65 and documented atherosclerosis or revascularization involving at least 2 vascular beds, or at least 2 additional risk factors

Exclusion Criteria:

* Stroke within 1 month or any history of hemorrhagic or lacunar stroke
* Severe heart failure with known ejection fraction \<30% or New York Heart Association (NYHA) class III or IV symptoms
* Estimated glomerular filtration rate (eGFR)\<15 mL/min
* Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy

Primary outcomes:
measure: The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death
timeFrame: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
measure: The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria
timeFrame: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Secondary outcomes:
measure: The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death
timeFrame: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
measure: The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death
timeFrame: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
measure: All-cause Mortality
timeFrame: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Other outcomes:
measure: The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part
timeFrame: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
measure: The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part
timeFrame: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
measure: All-cause Mortality in LTOLE Part
timeFrame: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
Locations:
city: Birmingham
country: United States
state: Alabama
city: Mobile
country: United States
state: Alabama
city: Anaheim
country: United States
state: California
city: Laguna Hills
country: United States
state: California
city: Northridge
country: United States
state: California
city: Palo Alto
country: United States
state: California
city: Santa Rosa
country: United States
state: California
city: Sylmar
country: United States
state: California
city: Torrance
country: United States
state: California
city: Norwalk
country: United States
state: Connecticut
city: Stamford
country: United States
state: Connecticut
city: Trumbull
country: United States
state: Connecticut
city: Atlantis
country: United States
state: Florida
city: Clearwater
country: United States
state: Florida
city: Coral Springs
country: United States
state: Florida
city: Jacksonville Beach
country: United States
state: Florida
city: Largo
country: United States
state: Florida
city: New Port Richey
country: United States
state: Florida
city: Safety Harbor
country: United States
state: Florida
city: Sarasota
country: United States
state: Florida
city: Meridian
country: United States
state: Idaho
city: Arlington Heights
country: United States
state: Illinois
city: Hazel Crest
country: United States
state: Illinois
city: Davenport
country: United States
state: Iowa
city: West Des Moines
country: United States
state: Iowa
city: Crestview Hills
country: United States
state: Kentucky
city: Baltimore
country: United States
state: Maryland
city: Haverhill
country: United States
state: Massachusetts
city: Alpena
country: United States
state: Michigan
city: Jackson
country: United States
state: Michigan
city: Saint Louis
country: United States
state: Missouri
city: Kalispell
country: United States
state: Montana
city: New Brunswick
country: United States
state: New Jersey
city: Cortlandt Manor
country: United States
state: New York
city: Kingston
country: United States
state: New York
city: Saratoga Springs
country: United States
state: New York
city: Durham
country: United States
state: North Carolina
city: Pinehurst
country: United States
state: North Carolina
city: Elyria
country: United States
state: Ohio
city: Sandusky
country: United States
state: Ohio
city: Toledo
country: United States
state: Ohio
city: Doylestown
country: United States
state: Pennsylvania
city: Langhorne
country: United States
state: Pennsylvania
city: Yardley
country: United States
state: Pennsylvania
city: Sioux Falls
country: United States
state: South Dakota
city: Dallas
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Bellevue
country: United States
state: Washington
city: Puyallup
country: United States
state: Washington
city: Seattle
country: United States
state: Washington
city: Spokane
country: United States
state: Washington
city: Adrogue
country: Argentina
state: Buenos Aires
city: Bahía Blanca
country: Argentina
state: Buenos Aires
city: Coronel Suarez
country: Argentina
state: Buenos Aires
city: Junín
country: Argentina
state: Buenos Aires
city: La Plata
country: Argentina
state: Buenos Aires
city: La Plata
country: Argentina
state: Buenos Aires
city: La Plata
country: Argentina
state: Buenos Aires
city: La Plata
country: Argentina
state: Buenos Aires
city: Mar del Plata
country: Argentina
state: Buenos Aires
city: Merlo
country: Argentina
state: Buenos Aires
city: Munro
country: Argentina
state: Buenos Aires
city: Quilmes
country: Argentina
state: Buenos Aires
city: Ramos Mejía
country: Argentina
state: Buenos Aires
city: San Martín
country: Argentina
state: Buenos Aires
city: San Nicolás
country: Argentina
state: Buenos Aires
city: Vicente López
country: Argentina
state: Buenos Aires
city: Zárate
country: Argentina
state: Buenos Aires
city: Buenos Aires
country: Argentina
state: Ciudad Auton. De Buenos Aires
city: Buenos Aires
country: Argentina
state: Ciudad Auton. De Buenos Aires
city: Buenos Aires
country: Argentina
state: Ciudad Auton. De Buenos Aires
city: Ciudad Autón. de Buenos Aires
country: Argentina
state: Ciudad Auton. De Buenos Aires
city: Villa Allende
country: Argentina
state: Córdoba
city: Villa María
country: Argentina
state: Córdoba
city: Santa Rosa
country: Argentina
state: La Pampa
city: Rafaela
country: Argentina
state: Santa Fe
city: Rosario
country: Argentina
state: Santa Fe
city: Rosario
country: Argentina
state: Santa Fe
city: Rosario
country: Argentina
state: Santa Fe
city: Venado Tuerto
country: Argentina
state: Santa Fe
city: San Miguel de Tucumán
country: Argentina
state: Tucuman
city: San Miguel de Tucumán
country: Argentina
state: Tucuman
city: Ciudad Auton. de Buenos Aires
country: Argentina
city: Ciudad Auton. de Buenos Aires
country: Argentina
city: Ciudad Auton. de Buenos Aires
country: Argentina
city: Corrientes
country: Argentina
city: Córdoba
country: Argentina
city: Córdoba
country: Argentina
city: Córdoba
country: Argentina
city: Córdoba
country: Argentina
city: Córdoba
country: Argentina
city: Córdoba
country: Argentina
city: Salta
country: Argentina
city: San Juan
country: Argentina
city: San luis
country: Argentina
city: Santa Fe
country: Argentina
city: Bruce
country: Australia
state: Australian Capital Territory
city: Gosford
country: Australia
state: New South Wales
city: New Lambton Heights
country: Australia
state: New South Wales
city: Taree
country: Australia
state: New South Wales
city: Birtinya
country: Australia
state: Queensland
city: Brisbane
country: Australia
state: Queensland
city: Brisbane
country: Australia
state: Queensland
city: Redcliffe
country: Australia
state: Queensland
city: Woolloongabba
country: Australia
state: Queensland
city: Adelaide
country: Australia
state: South Australia
city: Hobart
country: Australia
state: Tasmania
city: Launceston
country: Australia
state: Tasmania
city: Geelong
country: Australia
state: Victoria
city: Melbourne
country: Australia
state: Victoria
city: Melbourne
country: Australia
state: Victoria
city: Prahran
country: Australia
state: Victoria
city: Murdoch
country: Australia
state: Western Australia
city: Nedlands
country: Australia
state: Western Australia
city: Antwerpen
country: Belgium
city: Bonheiden
country: Belgium
city: Brugge
country: Belgium
city: Bruxelles - Brussel
country: Belgium
city: Charleroi
country: Belgium
city: Genk
country: Belgium
city: Hasselt
country: Belgium
city: Kortrijk
country: Belgium
city: Leuven
country: Belgium
city: Liege
country: Belgium
city: Roeselare
country: Belgium
city: Goiania
country: Brazil
state: Goiás
city: Belo Horizonte
country: Brazil
state: Minas Gerais
city: Uberaba
country: Brazil
state: Minas Gerais
city: Uberlândia
country: Brazil
state: Minas Gerais
city: Campina Grande do Sul
country: Brazil
state: Parana
city: Curitiba
country: Brazil
state: Parana
city: Canoas
country: Brazil
state: Rio Grande Do Sul
city: Pelotas
country: Brazil
state: Rio Grande Do Sul
city: Porto Alegre
country: Brazil
state: Rio Grande Do Sul
city: Porto Alegre
country: Brazil
state: Rio Grande Do Sul
city: Porto Alegre
country: Brazil
state: Rio Grande Do Sul
city: Porto Alegre
country: Brazil
state: Rio Grande Do Sul
city: Blumenau
country: Brazil
state: Santa Catarina
city: Campinas
country: Brazil
state: Sao Paulo
city: Campinas
country: Brazil
state: Sao Paulo
city: Campinas
country: Brazil
state: Sao Paulo
city: Matão
country: Brazil
state: Sao Paulo
city: São José do Rio Preto
country: Brazil
state: Sao Paulo
city: São José do Rio Preto
country: Brazil
state: Sao Paulo
city: São Paulo
country: Brazil
state: Sao Paulo
city: São Paulo
country: Brazil
state: Sao Paulo
city: Votuporanga
country: Brazil
state: Sao Paulo
city: Sao Paulo
country: Brazil
city: Calgary
country: Canada
state: Alberta
city: Edmonton
country: Canada
state: Alberta
city: New Westminster
country: Canada
state: British Columbia
city: Victoria
country: Canada
state: British Columbia
city: Winnipeg
country: Canada
state: Manitoba
city: Winnipeg
country: Canada
state: Manitoba
city: Winnipeg
country: Canada
state: Manitoba
city: Winnipeg
country: Canada
state: Manitoba
city: Moncton
country: Canada
state: New Brunswick
city: Saint John
country: Canada
state: New Brunswick
city: Halifax
country: Canada
state: Nova Scotia
city: Brampton
country: Canada
state: Ontario
city: Burlington
country: Canada
state: Ontario
city: Burlington
country: Canada
state: Ontario
city: Cambridge
country: Canada
state: Ontario
city: Cambridge
country: Canada
state: Ontario
city: Grimsby
country: Canada
state: Ontario
city: Hamilton
country: Canada
state: Ontario
city: Hamilton
country: Canada
state: Ontario
city: London
country: Canada
state: Ontario
city: London
country: Canada
state: Ontario
city: Mississauga
country: Canada
state: Ontario
city: Newmarket
country: Canada
state: Ontario
city: Newmarket
country: Canada
state: Ontario
city: Oakville
country: Canada
state: Ontario
city: Oshawa
country: Canada
state: Ontario
city: Oshawa
country: Canada
state: Ontario
city: Ottawa
country: Canada
state: Ontario
city: Peterborough
country: Canada
state: Ontario
city: Scarborough
country: Canada
state: Ontario
city: Sudbury
country: Canada
state: Ontario
city: Sudbury
country: Canada
state: Ontario
city: Toronto
country: Canada
state: Ontario
city: Waterloo
country: Canada
state: Ontario
city: Windsor
country: Canada
state: Ontario
city: Chicoutimi
country: Canada
state: Quebec
city: Laval
country: Canada
state: Quebec
city: Levis
country: Canada
state: Quebec
city: Montreal
country: Canada
state: Quebec
city: Montreal
country: Canada
state: Quebec
city: Sherbrooke
country: Canada
state: Quebec
city: Terrebonne
country: Canada
state: Quebec
city: Thetford Mines
country: Canada
state: Quebec
city: Trois-Rivieres
country: Canada
state: Quebec
city: Ontario
country: Canada
city: Quebec
country: Canada
city: Temuco
country: Chile
state: Araucanía
city: Temuco
country: Chile
state: Araucanía
city: Temuco
country: Chile
state: Araucanía
city: Concepción
country: Chile
state: Bío-Bío
city: Osorno
country: Chile
state: Los Lagos
city: Valdivia
country: Chile
state: Los Lagos
city: Providencia
country: Chile
state: Santiago
city: San Miguel
country: Chile
state: Santiago
city: Viña del Mar
country: Chile
state: Valparaíso
city: Santiago
country: Chile
city: Santiago
country: Chile
city: Guangzhou
country: China
state: Guangdong
city: Guangzhou
country: China
state: Guangdong
city: Wudan
country: China
state: Hubei
city: Wuhan
country: China
state: Hubei
city: Changsha
country: China
state: Hunan
city: Nanjing
country: China
state: Jiangsu
city: Nanjing
country: China
state: Jiangsu
city: Changchun
country: China
state: Jilin
city: Changchun
country: China
state: Jilin
city: Shenyang
country: China
state: Liaoning
city: Xi'an
country: China
state: Shanxi
city: Chengdu
country: China
state: Sichuan
city: Hangzhou
country: China
state: Zhejiang
city: Hangzhou
country: China
state: Zhejiang
city: Wenzhou
country: China
state: Zhejiang
city: Beijing
country: China
city: Beijing
country: China
city: Beijing
country: China
city: Beijing
country: China
city: Beijing
country: China
city: Beijing
country: China
city: Shanghai
country: China
city: Shanghai
country: China
city: Shanghai
country: China
city: Shanghai
country: China
city: Shanghai
country: China
city: Shanghai
country: China
city: Barranquilla
country: Colombia
state: Atlántico
city: Cartagena
country: Colombia
state: Bolívar
city: Manizales
country: Colombia
state: Caldas
city: Montería
country: Colombia
state: Córdoba
city: Pasto
country: Colombia
state: Nariño
city: Armenia
country: Colombia
state: Quindío
city: Pereira
country: Colombia
state: Risaralda
city: Bucaramanga
country: Colombia
state: Santander
city: Floridablanca
country: Colombia
state: Santander
city: Espinal
country: Colombia
state: Tolima
city: Cali
country: Colombia
state: Valle Del Cauca
city: Barranquilla
country: Colombia
city: Santafe de Bogotá
country: Colombia
city: Brno
country: Czechia
city: Brno
country: Czechia
city: Ceske Budejovice
country: Czechia
city: Cesky Krumlov
country: Czechia
city: Hodonin
country: Czechia
city: Hradec Kralove
country: Czechia
city: Jablonec nad Nisou
country: Czechia
city: Kolin
country: Czechia
city: Liberec
country: Czechia
city: Olomouc
country: Czechia
city: Ostrava
country: Czechia
city: Ostrava
country: Czechia
city: Pardubice
country: Czechia
city: Praha 10
country: Czechia
city: Praha 13
country: Czechia
city: Praha 2
country: Czechia
city: Praha 4
country: Czechia
city: Praha 5
country: Czechia
city: Praha 5
country: Czechia
city: Praha 6
country: Czechia
city: Slany
country: Czechia
city: Susice
country: Czechia
city: Trebic
country: Czechia
city: Trinec
country: Czechia
city: Uherske Hradiste
country: Czechia
city: Zlin
country: Czechia
city: Aalborg
country: Denmark
city: Aarhus N
country: Denmark
city: Hellerup
country: Denmark
city: Holbaek
country: Denmark
city: Hvidovre
country: Denmark
city: Kolding
country: Denmark
city: København Ø
country: Denmark
city: København
country: Denmark
city: Viborg
country: Denmark
city: Guayaquil
country: Ecuador
state: Guayas
city: Quito
country: Ecuador
state: Pichincha
city: Quito
country: Ecuador
city: Kuopio
country: Finland
city: Kuusankoski
country: Finland
city: Tampere
country: Finland
city: Turku
country: Finland
city: Vantaa
country: Finland
city: Amiens cedex 1
country: France
city: Clermont Ferrand
country: France
city: Limoges Cedex
country: France
city: Montpellier
country: France
city: Nice
country: France
city: NIMES cedex 9
country: France
city: Paris Cedex 15
country: France
city: Paris
country: France
city: Paris
country: France
city: Saint-priest-en-jarez
country: France
city: Nürnberg
country: Germany
state: Bayern
city: Würzburg
country: Germany
state: Bayern
city: Bad Homburg
country: Germany
state: Hessen
city: Frankfurt
country: Germany
state: Hessen
city: Kassel
country: Germany
state: Hessen
city: Bielefeld
country: Germany
state: Nordrhein-Westfalen
city: Dortmund
country: Germany
state: Nordrhein-Westfalen
city: Wuppertal
country: Germany
state: Nordrhein-Westfalen
city: Magdeburg
country: Germany
state: Sachsen-Anhalt
city: Dresden
country: Germany
state: Sachsen
city: Leipzig
country: Germany
state: Sachsen
city: Berlin
country: Germany
city: Berlin
country: Germany
city: Berlin
country: Germany
city: Bottrop
country: Germany
city: Frankfurt
country: Germany
city: Hamburg
country: Germany
city: Warendorf
country: Germany
city: Balatonfured
country: Hungary
city: Budapest
country: Hungary
city: Budapest
country: Hungary
city: Budapest
country: Hungary
city: Budapest
country: Hungary
city: Debrecen
country: Hungary
city: Mosonmagyarovar
country: Hungary
city: Pecs
country: Hungary
city: Sopron
country: Hungary
city: Szekesfehervar
country: Hungary
city: Szekszard
country: Hungary
city: Ballinasloe
country: Ireland
state: Co. Galway
city: Cork
country: Ireland
city: Dublin
country: Ireland
city: Dublin
country: Ireland
city: Dublin
country: Ireland
city: Galway
country: Ireland
city: Afula
country: Israel
city: Ashkelon
country: Israel
city: Bnei Brak
country: Israel
city: Haifa
country: Israel
city: Haifa
country: Israel
city: Holon
country: Israel
city: Nahariya
country: Israel
city: Tel Aviv
country: Israel
city: Tel Aviv
country: Israel
city: Zefat
country: Israel
city: Caserta
country: Italy
state: Campania
city: Bologna
country: Italy
state: Emilia-Romagna
city: Forlì Cesena
country: Italy
state: Emilia-Romagna
city: Ravenna
country: Italy
state: Emilia-Romagna
city: Trieste
country: Italy
state: Friuli-Venezia Giulia
city: Udine
country: Italy
state: Friuli-Venezia Giulia
city: Udine
country: Italy
state: Friuli-Venezia Giulia
city: Udine
country: Italy
state: Friuli-Venezia Giulia
city: Brescia
country: Italy
state: Lombardia
city: Cremona
country: Italy
state: Lombardia
city: Pavia
country: Italy
state: Lombardia
city: Ancona
country: Italy
state: Marche
city: Isernia
country: Italy
state: Molise
city: Foggia
country: Italy
state: Puglia
city: Lecce
country: Italy
state: Puglia
city: Catania
country: Italy
state: Sicilia
city: Palermo
country: Italy
state: Sicilia
city: Arezzo
country: Italy
state: Toscana
city: Firenze
country: Italy
state: Toscana
city: Perugia
country: Italy
state: Umbria
city: Terni
country: Italy
state: Umbria
city: Nagoya
country: Japan
state: Aichi
city: Toyoake
country: Japan
state: Aichi
city: Kisarazu
country: Japan
state: Chiba
city: Matsudo
country: Japan
state: Chiba
city: Imabari
country: Japan
state: Ehime
city: Matsuyama
country: Japan
state: Ehime
city: Kasuga
country: Japan
state: Fukuoka
city: Kitakyushu
country: Japan
state: Fukuoka
city: Miyako-gun
country: Japan
state: Fukuoka
city: Onga-gun
country: Japan
state: Fukuoka
city: Maebashi
country: Japan
state: Gunma
city: Onomichi
country: Japan
state: Hiroshima
city: Asahikawa
country: Japan
state: Hokkaido
city: Asahikawa
country: Japan
state: Hokkaido
city: Sapporo
country: Japan
state: Hokkaido
city: Sapporo
country: Japan
state: Hokkaido
city: Sapporo
country: Japan
state: Hokkaido
city: Tomakomai
country: Japan
state: Hokkaido
city: Kobe
country: Japan
state: Hyogo
city: Takarazuka
country: Japan
state: Hyogo
city: Kaga
country: Japan
state: Ishikawa
city: Miura-gun
country: Japan
state: Kanagawa
city: Sagamihara
country: Japan
state: Kanagawa
city: Yokohama
country: Japan
state: Kanagawa
city: Naha
country: Japan
state: Okinawa
city: Kishiwada
country: Japan
state: Osaka
city: Takatsuki
country: Japan
state: Osaka
city: Tokorozawa
country: Japan
state: Saitama
city: Komatsushima
country: Japan
state: Tokushima
city: Akishima
country: Japan
state: Tokyo
city: Bunkyo-ku
country: Japan
state: Tokyo
city: Itabashi-ku
country: Japan
state: Tokyo
city: Shimonoseki
country: Japan
state: Yamaguchi
city: Chiba
country: Japan
city: Fukuoka
country: Japan
city: Fukuoka
country: Japan
city: Gifu
country: Japan
city: Gifu
country: Japan
city: Kumamoto
country: Japan
city: Kyoto
country: Japan
city: Kyoto
country: Japan
city: Kyoto
country: Japan
city: Osaka
country: Japan
city: Osaka
country: Japan
city: Osaka
country: Japan
city: Osaka
country: Japan
city: Osaka
country: Japan
city: Osaka
country: Japan
city: Wonju
country: Korea, Republic of
state: Gang''weondo
city: Goyang-si
country: Korea, Republic of
state: Gyeonggido
city: Seongnam-si
country: Korea, Republic of
state: Gyeonggido
city: Jeju
country: Korea, Republic of
state: Jejudo
city: Seoul
country: Korea, Republic of
state: Seoul Teugbyeolsi
city: Busan
country: Korea, Republic of
city: Daejeon
country: Korea, Republic of
city: Seoul
country: Korea, Republic of
city: Seoul
country: Korea, Republic of
city: Seoul
country: Korea, Republic of
city: Batu Caves, Selangor
country: Malaysia
city: Kedah
country: Malaysia
city: Kuala Lumpur
country: Malaysia
city: Kuala Lumpur
country: Malaysia
city: Selangor
country: Malaysia
city: Sungai Buloh Selangor
country: Malaysia
city: Amsterdam
country: Netherlands
city: Apeldoorn
country: Netherlands
city: Arnhem
country: Netherlands
city: Breda
country: Netherlands
city: Delft
country: Netherlands
city: Den Bosch
country: Netherlands
city: Deventer
country: Netherlands
city: Doetinchem
country: Netherlands
city: Drachten
country: Netherlands
city: EDE
country: Netherlands
city: Gorinchem
country: Netherlands
city: Gouda
country: Netherlands
city: Groningen
country: Netherlands
city: Heerlen
country: Netherlands
city: Helmond
country: Netherlands
city: Hoogeveen
country: Netherlands
city: Hoorn
country: Netherlands
city: Leeuwarden
country: Netherlands
city: Meppel
country: Netherlands
city: Nijmegen
country: Netherlands
city: Roermond
country: Netherlands
city: Roosendaal
country: Netherlands
city: Rotterdam
country: Netherlands
city: Rotterdam
country: Netherlands
city: Sneek
country: Netherlands
city: Tiel
country: Netherlands
city: Zwolle
country: Netherlands
city: Batangas
country: Philippines
city: Cebu City
country: Philippines
city: Dagupan City
country: Philippines
city: Dasmarinas
country: Philippines
city: Iloilo City
country: Philippines
city: Laoag City
country: Philippines
city: Manila
country: Philippines
city: Manila
country: Philippines
city: Metro Manila
country: Philippines
city: Muntinlupa City
country: Philippines
city: Palawan
country: Philippines
city: Pasig city
country: Philippines
city: Quezon City
country: Philippines
city: Quezon City
country: Philippines
city: Quezon City
country: Philippines
city: Tacloban City
country: Philippines
city: Gdansk
country: Poland
city: Kielce
country: Poland
city: Krakow
country: Poland
city: Krakow
country: Poland
city: Krakow
country: Poland
city: Krakow
country: Poland
city: Lodz
country: Poland
city: Tarnow
country: Poland
city: Wroclaw
country: Poland
city: Timisoara
country: Romania
state: Timis
city: Brasov
country: Romania
city: Bucharest
country: Romania
city: Bucharest
country: Romania
city: Bucharest
country: Romania
city: Bucharest
country: Romania
city: Bucharest
country: Romania
city: Bucharest
country: Romania
city: Bucharest
country: Romania
city: Bucuresti
country: Romania
city: Cluj Napoca
country: Romania
city: Iasi
country: Romania
city: Iasi
country: Romania
city: Targu Mures
country: Romania
city: Targu Mures
country: Romania
city: Timisoara
country: Romania
city: Barnaul
country: Russian Federation
city: Kemerovo
country: Russian Federation
city: Moscow
country: Russian Federation
city: Moscow
country: Russian Federation
city: Moscow
country: Russian Federation
city: Moscow
country: Russian Federation
city: Moscow
country: Russian Federation
city: Moscow
country: Russian Federation
city: Moscow
country: Russian Federation
city: Novosibirsk
country: Russian Federation
city: Tomsk
country: Russian Federation
city: Zhukovskiy
country: Russian Federation
city: Bratislava
country: Slovakia
city: Bratislava
country: Slovakia
city: Kosice
country: Slovakia
city: Nitra
country: Slovakia
city: Presov
country: Slovakia
city: Vrable
country: Slovakia
city: Pinelands
country: South Africa
state: Eastern Cape
city: Port Elizabeth
country: South Africa
state: Eastern Cape
city: Bloemfontein
country: South Africa
state: Freestate
city: Johannesburg
country: South Africa
state: Gauteng
city: Cape Town
country: South Africa
state: Western Cape
city: Observatory
country: South Africa
state: Western Cape
city: Pinelands
country: South Africa
state: Western Cape
city: Worcester
country: South Africa
state: Western Cape
city: Somerset West
country: South Africa
city: Göteborg
country: Sweden
city: Helsingborg
country: Sweden
city: Kristianstad
country: Sweden
city: Skellefteå
country: Sweden
city: Stockholm
country: Sweden
city: Stockholm
country: Sweden
city: Stockholm
country: Sweden
city: Stockholm
country: Sweden
city: Vällingby
country: Sweden
city: Örebro
country: Sweden
city: Östersund
country: Sweden
city: Lugano
country: Switzerland
state: Ticino
city: Dnipropetrovsk
country: Ukraine
city: Kharkiv
country: Ukraine
city: Kharkiv
country: Ukraine
city: Kharkiv
country: Ukraine
city: Kiev
country: Ukraine
city: Kiev
country: Ukraine
city: Kiev
country: Ukraine
city: Lviv
country: Ukraine
city: Lviv
country: Ukraine
city: Lviv
country: Ukraine
city: Simferopol
country: Ukraine
city: Vinnitsa
country: Ukraine
city: Zaporozhye
country: Ukraine
city: Zaporozhye
country: Ukraine
city: Belfast
country: United Kingdom
state: Antrim
city: Londonderry Co. Londonderry
country: United Kingdom
state: Derry
city: Basildon
country: United Kingdom
state: Essex
city: Stevenage
country: United Kingdom
state: Hertfordshire
city: Blackpool
country: United Kingdom
state: Lancashire
city: Harrow
country: United Kingdom
state: London
city: Portadown
country: United Kingdom
state: North Ireland
city: Middlesborough
country: United Kingdom
state: North Yorkshire
city: Northampton
country: United Kingdom
state: Northamptonshire
city: Hardwick
country: United Kingdom
state: Stockton-on-Tees
city: Nuneaton
country: United Kingdom
state: Warwickshire
city: West Bromich
country: United Kingdom
state: West Midlands
city: Wolverhampton
country: United Kingdom
state: West Midlands
city: Worcester
country: United Kingdom
state: Worcestershire
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
citation: Eikelboom JW, Bosch J, Connolly SJ, Tyrwitt J, Fox KAA, Muehlhofer E, Neumann C, Tasto C, Bangdiwala SI, Diaz R, Alings M, Dagenais GR, Leong DP, Lonn EM, Avezum A, Piegas LS, Widimsky P, Parkhomenko AN, Bhatt DL, Branch KRH, Probstfield JL, Lopez-Jaramillo P, Ryden L, Pogosova N, Keltai K, Keltai M, Ertl G, Stoerk S, Dans AL, Lanas F, Liang Y, Zhu J, Torp-Pedersen C, Maggioni AP, Commerford PJ, Guzik TJ, Vanassche T, Verhamme P, O'Donnell M, Tonkin AM, Varigos JD, Vinereanu D, Felix C, Kim JH, Ibrahim KS, Lewis BS, Metsarinne KP, Aboyans V, Steg PG, Hori M, Kakkar A, Anand SS, Lamy A, Sharma M, Yusuf S. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 2;8(8):786-795. doi: 10.1093/ehjcvp/pvac023.
citation: Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, Abola MT, Branch KRH, Keltai K, Bhatt DL, Verhamme P, Fox KAA, Cook-Bruns N, Lanius V, Connolly SJ, Yusuf S. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. J Am Coll Cardiol. 2018 May 22;71(20):2306-2315. doi: 10.1016/j.jacc.2018.03.008. Epub 2018 Mar 11.
citation: Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Nov 10. pii: S0140-6736(17)32409-1. doi: 10.1016/S0140-6736(17)32409-1. PMID:29132880
citation: Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Nov 10. pii: S0140-6736(17)32458-3. doi: 10.1016/S0140-6736(17)32458-3. PMID:29132879
citation: Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.
citation: Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M, Lonn EM, Widimsky P, Hori M, Avezum A, Piegas LS, Bhatt DL, Branch KRH, Probstfield JL, Liang Y, Liu L, Zhu J, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Fox KAA, Kakkar A, Parkhomenko AN, Ertl G, Stork S, Keltai K, Keltai M, Ryden L, Dagenais GR, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Ha JW, Tonkin AM, Varigos JD, Lewis BS, Felix C, Yusoff K, Steg PG, Aboyans V, Metsarinne KP, Anand SS, Hart RG, Lamy A, Moayyedi P, Leong DP, Sharma M, Yusuf S. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017 Aug;33(8):1027-1035. doi: 10.1016/j.cjca.2017.06.001. Epub 2017 Jun 8.
citation: Braunwald E. An Important Step for Thrombocardiology. N Engl J Med. 2017 Oct 5;377(14):1387-1388. doi: 10.1056/NEJMe1710241. Epub 2017 Aug 27. No abstract available.
citation: Fauchier L, Bisson A, Angoulvant D. Rivaroxaban in Stable Cardiovascular Disease. N Engl J Med. 2018 Jan 26;378(4):395. doi: 10.1056/NEJMc1714934. No abstract available.
citation: Berger JS. Antithrombotic therapy in peripheral artery disease. Lancet. 2018 Jan 20;391(10117):183-184. doi: 10.1016/S0140-6736(17)32847-7. Epub 2017 Nov 10. No abstract available.
citation: Darmon A, Bhatt DL, Elbez Y, Aboyans V, Anand S, Bosch J, Branch KR, Connolly SJ, Dyal L, Eikelboom JW, Fox KAA, Keltai K, Probstfield J, Yusuf S, Abtan J, Sorbets E, Eagle KA, Ducrocq G, Steg PG. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J. 2018 Mar 1;39(9):750-757a. doi: 10.1093/eurheartj/ehx658.
citation: Verheugt FWA. Return of Oral Anticoagulation in Chronic Stable Coronary Disease. Circulation. 2018 Apr 17;137(16):1655-1657. doi: 10.1161/CIRCULATIONAHA.117.032916. No abstract available.
citation: Fox KAA, Eikelboom JW, Anand SS, Bhatt DL, Bosch J, Connolly SJ, Harrington RA, Steg PG, Yusuf S. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Eur Heart J. 2019 May 7;40(18):1466-1471. doi: 10.1093/eurheartj/ehy347. No abstract available.
citation: Sharma M, Hart RG, Smith EE, Bosch J, Yuan F, Casanova A, Eikelboom JW, Connolly SJ, Wong G, Diaz R, Lopez-Jaramillo P, Ertl G, Stork S, Dagenais GR, Lonn EM, Ryden L, Tonkin AM, Varigos JD, Bhatt DL, Branch KR, Probstfield JL, Kim JH, Ha JW, O'Donnell M, Vinereanu D, Fox KA, Liang Y, Liu L, Zhu J, Pogosova N, Maggioni AP, Avezum A, Piegas LS, Keltai K, Keltai M, Cook Bruns N, Berkowitz S, Yusuf S. Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. Int J Stroke. 2019 Apr;14(3):270-281. doi: 10.1177/1747493018784478. Epub 2018 Jul 30.
citation: Kruger PC, Eikelboom JW, Yusuf S. Rivaroxaban with or without aspirin for prevention of cardiovascular disease. Coron Artery Dis. 2018 Aug;29(5):361-365. doi: 10.1097/MCA.0000000000000605. No abstract available.
citation: Ademi Z, Zomer E, Tonkin A, Liew D. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. Int J Cardiol. 2018 Nov 1;270:54-59. doi: 10.1016/j.ijcard.2018.06.091. Epub 2018 Jun 25.
citation: Bhagirath VC, Eikelboom JW, Anand SS. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. Future Cardiol. 2018 Nov;14(6):443-453. doi: 10.2217/fca-2018-0059. Epub 2018 Nov 12.
citation: Kruger PC, Anand SS, de Vries TAC, Eikelboom JW. Patients with Peripheral Artery Disease in the COMPASS Trial. Eur J Vasc Endovasc Surg. 2018 Dec;56(6):772-773. doi: 10.1016/j.ejvs.2018.08.010. Epub 2018 Sep 10. No abstract available.
citation: Boden WE, Bhatt DL. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease? Circulation. 2018 Aug 28;138(9):858-860. doi: 10.1161/CIRCULATIONAHA.118.035405. No abstract available.
citation: Lamy A, Eikelboom J, Sheth T, Connolly S, Bosch J, Fox KAA, Zhu J, Lonn E, Dagenais G, Widimsky P, Branch KRH, Bhatt DL, Zheng Z, Straka Z, Dagenais F, Kong Y, Marsden T, Lee SF, Copland I, Yusuf S. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. J Am Coll Cardiol. 2019 Jan 22;73(2):121-130. doi: 10.1016/j.jacc.2018.10.048.
citation: Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH, Catanese L, Keltai K, Aboyans V, Alings M, Ha JW, Varigos J, Tonkin A, O'Donnell M, Bhatt DL, Fox K, Maggioni A, Berkowitz SD, Bruns NC, Yusuf S, Eikelboom JW. Stroke Outcomes in the COMPASS Trial. Circulation. 2019 Feb 26;139(9):1134-1145. doi: 10.1161/CIRCULATIONAHA.118.035864.
citation: Coppens M, Weitz JI, Eikelboom JWA. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. Circ Res. 2019 Feb;124(3):416-425. doi: 10.1161/CIRCRESAHA.118.313141.
citation: Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Stork S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Cook Bruns N, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar A, Parkhomenko AN, Ryden L, Pogosova N, Dans A, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik T, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne K, Fox KAA, Yusuf S; COMPASS Investigators. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 2019 Aug;157(2):403-412.e5. doi: 10.1053/j.gastro.2019.04.041. Epub 2019 May 2.
citation: Fox KAA, Eikelboom JW, Shestakovska O, Connolly SJ, Metsarinne KP, Yusuf S. Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. J Am Coll Cardiol. 2019 May 14;73(18):2243-2250. doi: 10.1016/j.jacc.2019.02.048.
citation: Cairns JA, Eikelboom JW, Shestakovska O, Yusuf S, DeMets D. Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. J Am Coll Cardiol. 2019 Jun 4;73(21):2769-2772. doi: 10.1016/j.jacc.2019.03.479. No abstract available.
citation: Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Stork S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS Investigators. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019 Sep;157(3):682-691.e2. doi: 10.1053/j.gastro.2019.05.056. Epub 2019 May 29.
citation: Kruger PC, Guzik TJ, Eikelboom JW. How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? Kardiol Pol. 2019 Aug 23;77(7-8):661-669. doi: 10.33963/KP.14855. Epub 2019 May 30.
citation: Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK, Bhatt DL, Avezum A, Fox KAA, Connolly SJ, Shestakovska O, Yusuf S. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation. 2019 Aug 13;140(7):529-537. doi: 10.1161/CIRCULATIONAHA.119.039609. Epub 2019 Jun 5.
citation: Darmon A, Sorbets E, Ducrocq G, Elbez Y, Abtan J, Popovic B, Ohman EM, Rother J, Wilson PF, Montalescot G, Zeymer U, Bhatt DL, Steg PG; REACH Registry Investigators. Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. J Am Coll Cardiol. 2019 Jul 2;73(25):3281-3291. doi: 10.1016/j.jacc.2019.04.046.
citation: Anand SS, Eikelboom JW, Dyal L, Bosch J, Neumann C, Widimsky P, Avezum AA, Probstfield J, Cook Bruns N, Fox KAA, Bhatt DL, Connolly SJ, Yusuf S; COMPASS Trial Investigators. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. J Am Coll Cardiol. 2019 Jul 2;73(25):3271-3280. doi: 10.1016/j.jacc.2019.02.079.
citation: Fox KAA, Metra M, Morais J, Atar D. The myth of 'stable' coronary artery disease. Nat Rev Cardiol. 2020 Jan;17(1):9-21. doi: 10.1038/s41569-019-0233-y. Epub 2019 Jul 29.
citation: de Vries TI, Eikelboom JW, Bosch J, Westerink J, Dorresteijn JAN, Alings M, Dyal L, Berkowitz SD, van der Graaf Y, Fox KAA, Visseren FLJ. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. Eur Heart J. 2019 Dec 7;40(46):3771-3778a. doi: 10.1093/eurheartj/ehz404.
citation: Eikelboom JW, Connolly SJ, Bosch J, Shestakovska O, Aboyans V, Alings M, Anand SS, Avezum A, Berkowitz SD, Bhatt DL, Cook-Bruns N, Felix C, Fox KAA, Hart RG, Maggioni AP, Moayyedi P, O'Donnell M, Ryden L, Verhamme P, Widimsky P, Zhu J, Yusuf S. Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation. 2019 Oct 29;140(18):1451-1459. doi: 10.1161/CIRCULATIONAHA.119.041949. Epub 2019 Sep 12.
citation: Perera KS, Ng KKH, Nayar S, Catanese L, Dyal L, Sharma M, Connolly SJ, Yusuf S, Bosch J, Eikelboom JW, Hart RG. Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. JAMA Neurol. 2020 Jan 1;77(1):43-48. doi: 10.1001/jamaneurol.2019.2984.
citation: Eikelboom JW, Bosch JJ, Connolly SJ, Shestakovska O, Dagenais GR, Hart RG, Leong DP, O'Donnell M, Fox KAA, Bhatt DL, Cairns JA, Tasto C, Berkowitz SD, Cook Bruns N, Muehlhofer E, Diaz R, Maggioni AP, Yusuf S. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. J Am Coll Cardiol. 2019 Sep 24;74(12):1519-1528. doi: 10.1016/j.jacc.2019.07.065.
citation: Wurtz M, Olesen KKW, Thim T, Kristensen SD, Eikelboom JW, Maeng M. External applicability of the COMPASS trial: the Western Denmark Heart Registry. Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):192-199. doi: 10.1093/ehjcvp/pvz013.
citation: Vanassche T, Verhamme P, Anand SS, Shestakovska O, Fox KA, Bhatt DL, Avezum A, Alings M, Aboyans V, Maggioni AP, Widimsky P, Berkowitz SD, Yusuf S, Connolly SJ, Eikelboom JW, Bosch J. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. Eur J Prev Cardiol. 2020 Feb;27(3):296-307. doi: 10.1177/2047487319882154. Epub 2019 Oct 15.
citation: Cowie MR, Lamy A, Levy P, Mealing S, Millier A, Mernagh P, Cristeau O, Bowrin K, Briere JB. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. Cardiovasc Res. 2020 Sep 1;116(11):1918-1924. doi: 10.1093/cvr/cvz278.
citation: Welsh RC, Peterson ED, De Caterina R, Bode C, Gersh B, Eikelboom JW. Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. Am Heart J. 2019 Dec;218:100-109. doi: 10.1016/j.ahj.2019.09.006. Epub 2019 Oct 23.
citation: Schiele F, Puymirat E, Ferrieres J, Simon T, Fox KAA, Eikelboom J, Danchin N; FAST-MI investigators. The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. Int J Cardiol. 2019 Mar 1;278:7-13. doi: 10.1016/j.ijcard.2018.11.138. Epub 2018 Dec 3.
citation: Bainey KR, Welsh RC, Connolly SJ, Marsden T, Bosch J, Fox KAA, Steg PG, Vinereanu D, Connolly DL, Berkowitz SD, Foody JM, Probstfield JL, Branch KR, Lewis BS, Diaz R, Muehlhofer E, Widimsky P, Yusuf S, Eikelboom JW, Bhatt DL; COMPASS Investigators. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 2020 Apr 7;141(14):1141-1151. doi: 10.1161/CIRCULATIONAHA.119.044598. Epub 2020 Mar 17.
citation: Liang Y, Zhu J, Liu L, Anand SS, Connolly SJ, Bosch J, Guzik TJ, O'Donnell M, Dagenais GR, Fox KA, Shestakovska O, Berkowitz SD, Muehlhofer E, Keller L, Yusuf S, Eikelboom JW; COMPASS Investigators. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. Cardiovasc Res. 2021 Feb 22;117(3):942-949. doi: 10.1093/cvr/cvaa100.
citation: Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, Branch KRH, Probstfield J, Bosch J, Shestakovska O, Szarek M, Maggioni AP, Widimsky P, Avezum A, Diaz R, Lewis BS, Berkowitz SD, Fox KAA, Ryden L, Yusuf S; COMPASS Steering Committee and Investigators. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. Circulation. 2020 Jun 9;141(23):1841-1854. doi: 10.1161/CIRCULATIONAHA.120.046448. Epub 2020 Mar 28.
citation: Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. Circulation. 2020 Jul 7;142(1):40-48. doi: 10.1161/CIRCULATIONAHA.120.046048. Epub 2020 May 21.
citation: Sharma M, Hart RG, Smith EE, Bosch J, Eikelboom JW, Connolly SJ, Dyal L, Reeh KW, Casanova A, Diaz R, Lopez-Jaramillo P, Ertl G, Stork S, Dagenais GR, Lonn EM, Ryden L, Tonkin AM, Varigos JD, Bhatt DL, Branch KRH, Probstfield JL, Kim JH, O'Donnell M, Vinereanu D, A A Fox K, Liang Y, Liu L, Zhu J, Pogosova N, Maggioni AP, Avezum A, Piegas LS, Keltai K, Keltai M, Berkowitz SD, Yusuf S. Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. Stroke. 2020 Oct;51(10):2901-2909. doi: 10.1161/STROKEAHA.120.029762. Epub 2020 Sep 21.
citation: Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, Avezum A, Fox KAA, Berkowitz SD, Bangdiwala SI, Yusuf S, Anand SS. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. JAMA Cardiol. 2021 Jan 1;6(1):21-29. doi: 10.1001/jamacardio.2020.4390.
citation: Guzik TJ, Ramasundarahettige C, Pogosova N, Lopez-Jaramillo P, Dyal L, Berkowitz SD, Muehlhofer E, Bhatt DL, Fox KAA, Yusuf S, Eikelboom JW. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. J Am Coll Cardiol. 2021 Feb 9;77(5):511-525. doi: 10.1016/j.jacc.2020.11.061.
citation: Sen J, Tonkin A, Varigos J, Fonguh S, Berkowitz SD, Yusuf S, Verhamme P, Vanassche T, Anand SS, Fox KAA, Eikelboom JW, Amerena J; COMPASS Trial Investigators. Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. Int J Cardiol. 2021 Aug 15;337:9-15. doi: 10.1016/j.ijcard.2021.04.067. Epub 2021 May 3.
citation: Dagenais GR, Dyal L, Bosch JJ, Leong DP, Aboyans V, Berkowitz SD, Bhatt DL, Connolly SJ, Fox KAA, Muehlhofer E, Probstfield JL, Widimsky P, Winkelmann BR, Yusuf S, Eikelboom JW. Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart. 2021 Jul;107(14):1130-1137. doi: 10.1136/heartjnl-2020-318758. Epub 2021 May 21.
citation: Lamy A, Browne A, Sheth T, Zheng Z, Dagenais F, Noiseux N, Chen X, Bakaeen FG, Brtko M, Stevens LM, Alboom M, Lee SF, Copland I, Salim Y, Eikelboom J; COMPASS Investigators. Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial. JAMA Cardiol. 2021 Sep 1;6(9):1042-1049. doi: 10.1001/jamacardio.2021.1686.
citation: Vanassche T, Verhamme P, Anand SS, Shestakovska O, Leong DP, Fox KAA, Bhatt DL, Avezum A, Alings M, Aboyans V, Maggioni AP, Widimsky P, Muehlhofer E, Berkowitz SD, Yusuf S, Connolly SJ, Eikelboom JW, Bosch J. Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. Eur Heart J Cardiovasc Pharmacother. 2022 Aug 11;8(5):462-473. doi: 10.1093/ehjcvp/pvab050.
citation: Eikelboom JW, Bhatt DL, Fox KAA, Bosch J, Connolly SJ, Anand SS, Avezum A, Berkowitz SD, Branch KRH, Dagenais GR, Felix C, Guzik TJ, Hart RG, Maggioni AP, Muehlhofer E, Sharma M, Shestakovska O, Yusuf S. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. J Am Coll Cardiol. 2021 Jul 6;78(1):14-23. doi: 10.1016/j.jacc.2021.04.083.
citation: Anand SS, Hiatt W, Dyal L, Bauersachs R, Berkowitz SD, Branch KRH, Debus S, Fox KAA, Liang Y, Muehlhofer E, Nehler M, Haskell LP, Patel M, Szarek M, Yusuf S, Eikelboom J, Bonaca MP. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. Eur J Prev Cardiol. 2022 May 5;29(5):e181-e189. doi: 10.1093/eurjpc/zwab128.
citation: Kaplovitch E, Anand SS. The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era. Cardiovasc Res. 2019 Oct 1;115(12):e121-e124. doi: 10.1093/cvr/cvz170. No abstract available.
citation: Lamy A, Eikelboom J, Tong W, Yuan F, Bangdiwala SI, Bosch J, Connolly S, Lonn E, Dagenais GR, Branch KRH, Wang WJ, Bhatt DL, Probstfield J, Ertl G, Stork S, Steg PG, Aboyans V, Durand-Zaleski I, Ryden L, Yusuf S. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. Eur Heart J Qual Care Clin Outcomes. 2023 Aug 7;9(5):502-510. doi: 10.1093/ehjqcco/qcac054.
citation: Catanese L, Eikelboom JW, Bosch J, Shestakovska O, Ng K, Nayar S, Perera KS, Shoamanesh A, Sharma M, Hart RG. Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis. Neurology. 2020 Aug 4;95(5):e480-e487. doi: 10.1212/WNL.0000000000009826. Epub 2020 Jul 10.
citation: Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Stork S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1. Epub 2017 Nov 10.
citation: Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):205-218. doi: 10.1016/S0140-6736(17)32458-3. Epub 2017 Nov 10.